Search Within

Biostatistics Service

Formats
  1. Journal Article (4043)
  2. Meeting Abstract (2452)
  3. Research Letter (55)
  4. Conference Paper (37)
  5. Correspondence (28)
  6. Editorial (25)
  7. Review (23)
  8. Miscellaneous (16)
  9. Book Section (13)
  10. Book Whole (3)
  11. Guidelines (2)
Groups
  1. Epidemiology and Biostatistics (6697)
  2. Department of Medicine (3944)
  3. Solid Tumor Oncology Division (2622)
  4. Survivorship Research (2547)
  5. Surgery (2419)
  6. Population Sciences Research Program (2406)

More Groups

People
  1. Mithat Gonen (1037)
  2. Sean Devlin (616)
  3. Katherine Panageas (523)
  4. Sujata Patil (511)
  5. Sergio Giralt (480)
  6. Zhigang Zhang (432)

More People

Years
  1. 2025 (214)
  2. 2024 (399)
  3. 2023 (411)
  4. 2022 (407)
  5. 2021 (369)
  6. 2020 (394)

More Years

Publications
  1. Journal of Clinical Oncology (1077)
  2. Blood (468)
  3. Annals of Surgical Oncology (312)
  4. International Journal of Radiation Oncology, Biology, Physics (233)
  5. Clinical Cancer Research (198)
  6. Biology of Blood and Marrow Transplantation (174)

More Publications

Publishers
  1. American Society of Clinical Oncology (1146)
  2. Elsevier Inc. (780)
  3. Springer (633)
  4. American Society of Hematology (526)
  5. American Association for Cancer Research (433)
  6. Nature Publishing Group (317)

More Publishers

Results (6697)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Stereotactic radio-surgery in the treatment of brain metastases from radioresistant tumors
    Meeting Abstract

    Narayana, A.; Patil, S.; Diamond, S.; Yamada, Y.; Gutin, P. H.
    Journal of Clinical Oncology (2005)

    Fulltext@MSK | Save
  • Pentostatin, cyclophosphamide, and rituximab (PCR) has comparable activity but appears to be better tolerated than fludarabine, cyclophosphamide, and rituximab (FCR) in patients with previously treated chronic lymphocytic leukemia
    Meeting Abstract

    Lamanna, N.; Kalaycio, M.; Maslak, P.; Heaney, M. L.; Brentjens, R.; Jurcic, J.; Biederman, E.; Gencarelli, A. N.; Panageas, K. S.; Scheinberg, D. A.; more...
    Blood (2005)

    Fulltext@MSK | Save
  • Phase I trial of hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone (DEX) in combination with systemic oxaliplatin (OXAL), fluorouracil (FU) plus loucovorin (LV) after resection of hepatic metastases from colorectal cancer
    Meeting Abstract

    Kemeny, N. E.; Jarnagin, W.; Gonen, M.; Haviland, D.; D'Angelica, M.; Blumgart, L.; DeMatteo, R.; Schwartz, L.; Fong, Y.
    Journal of Clinical Oncology (2005)

    Fulltext@MSK | Save
  • Effect of adjuvant chemotherapy (CRx) on the cognitive function of older patients (pts) with breast cancer (BC): Results from a prospective study
    Meeting Abstract

    Hurria, A.; Rosen, C.; Zuckerman, E.; Holland, J.; Panageas, K.; Witmer, M.; van Gorp, W.; Norton, L.; Hudis, C.
    Journal of Clinical Oncology (2005)

    Fulltext@MSK | Save
  • A prospective longitudinal study of the impact of adjuvant chemotherapy for breast cancer (BC) on older patients' functional status and quality of life
    Meeting Abstract

    Hurria, A.; Panageas, K.; Zuckerman, E.; Fornier, M.; D'Andrea, G.; Dang, C.; Moasser, M.; Robson, M.; Seidman, A.; Currie, V.; more...
    Breast Cancer Research and Treatment (2005)

    Fulltext@MSK | Save
  • Prospective analysis of matrix metalloproteinase-9 (MMP-9) in the serum of patients with high-grade gliomas
    Meeting Abstract

    Hormigo, A.; Gu, B.; Riedel, E.; Rao, J.; Fleisher, M.; Panageas, K.; DeAngelis, L.; Holland, E.
    Neuro-Oncology (2005)

    Fulltext@MSK | Save
  • Paclitaxel, carboplatin plus gemcitabine (PCG) as first-line treatment for advanced epithelial ovarian cancer (EOC): Pathologic complete response (pCR) and impact on cognitive functioning
    Meeting Abstract

    Hensley, M. L.; Correa, D.; Thaler, H.; Wilton, A.; Venkatraman, E.; Sabbatini, P.; Chi, D.; Spriggs, D.; Aghajanian, C.
    Journal of Clinical Oncology (2005)

    Fulltext@MSK | Save
  • Increased dose-density (DD) is feasible: A pilot study of epirubicin and cyclophosphamide (EC) followed by paclitaxel (T), at 10-11 day interval with filgrastim support, for women with early breast carcinoma (BC)
    Meeting Abstract

    Fornier, M. N.; Seidman, A. D.; Lake, D.; D'Andrea, G.; Bromberg, J.; Robson, M.; Van Poznak, C. H.; Panageas, K.; Norton, L.; Hudis, C.
    Journal of Clinical Oncology (2005)

    Fulltext@MSK | Save
  • Decreased PET SUV after induction chemotherapy is associated with improved survival in malignant pleural mesothelioma (MPM)
    Meeting Abstract

    Flores, R. M.; Akhurst, T.; Krug, L.; Gonen, M.; Dycoco, J.; Rosenzweig, K.; Larson, S. M.; Downey, R. J.; Rusch, V. W.
    Journal of Clinical Oncology (2005)

    Fulltext@MSK | Save
  • Malignant pleural mesothelioma (MPM): New predictors of survival and an analysis of the impact of current treatment
    Meeting Abstract

    Flores, R.; Zakowski, M.; Venkatraman, E.; Krug, L.; Rosenzweig, K.; Dycoco, J.; Yeoh, C.; Lee, C.; Bains, M.; Rusch, V.
    Lung Cancer (2005)

    Fulltext@MSK | Save